Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (31-40 of 436) with videos related to

Pageof 44
Sort By:
The New England Journal of Medicine|January 26, 2017
Systemic Therapy for Metastatic Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer
The New England Journal of Medicine|November 15, 2013
Pazopanib versus sunitinib in renal cancerRobert J Motzer, Lauren McCann, Keith Deen
European Urology|November 12, 2017
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8Robert J Motzer, Bernard Escudier, Alain Ravaud
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experienceRobert J Motzer, Jennifer Bacik, Madhu Mazumdar
The Lancet. Oncology|April 30, 2022
Patient-reported outcomes: what really matters to patients? - Authors' replyDavid Cella, Toni K Choueiri, Robert J Motzer
Cancer Treatment and Research|December 4, 2003
Prognostic factors for metastatic kidney cancerBeverly J Drucker, Madhu Mazumdar, Robert J Motzer
BJU International|February 21, 2008
Sunitinib therapy in renal cell carcinomaMatthew F O'Brien, Paul Russo, Robert J Motzer
The New England Journal of Medicine|March 11, 2016
Treatment of Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, Toni K Choueiri
The New England Journal of Medicine|August 2, 2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. ReplyToni K Choueiri, Fong Wang, Robert J Motzer
Seminars in Oncology|July 19, 2003
Recommendations of follow-up after treatment of germ cell tumorsG Varuni Kondagunta, Joel Sheinfeld, Robert J Motzer
Pageof 44

Showing results (31-40 of 436) with videos related to

Sort By:
Pageof 44
The New England Journal of Medicine|January 26, 2017
Systemic Therapy for Metastatic Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer
The New England Journal of Medicine|November 15, 2013
Pazopanib versus sunitinib in renal cancerRobert J Motzer, Lauren McCann, Keith Deen
European Urology|November 12, 2017
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8Robert J Motzer, Bernard Escudier, Alain Ravaud
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experienceRobert J Motzer, Jennifer Bacik, Madhu Mazumdar
The Lancet. Oncology|April 30, 2022
Patient-reported outcomes: what really matters to patients? - Authors' replyDavid Cella, Toni K Choueiri, Robert J Motzer
Cancer Treatment and Research|December 4, 2003
Prognostic factors for metastatic kidney cancerBeverly J Drucker, Madhu Mazumdar, Robert J Motzer
BJU International|February 21, 2008
Sunitinib therapy in renal cell carcinomaMatthew F O'Brien, Paul Russo, Robert J Motzer
The New England Journal of Medicine|March 11, 2016
Treatment of Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, Toni K Choueiri
The New England Journal of Medicine|August 2, 2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. ReplyToni K Choueiri, Fong Wang, Robert J Motzer
Seminars in Oncology|July 19, 2003
Recommendations of follow-up after treatment of germ cell tumorsG Varuni Kondagunta, Joel Sheinfeld, Robert J Motzer
Pageof 44